Oculis Holding AG
Open
$27.17
Prev. Close
$27.17
High
$27.20
Low
$27.15
Market Snapshot
$1.48B
-11.8
-2.36
49
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 60 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
emptyResult
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 60 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.